Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 15/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD1 | P21728 | 1/20 | 0.40 |
| ▸ | DRD5 | P21918 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6278814 | 0.95 | CFTR (0.51) | CFTRKDM4EMEN1KMT2ANPSR1 | |
| SCHEMBL6275137 | 0.92 | CFTR (0.49) | CFTRKDM4EMEN1KMT2ANPSR1 | |
| SCHEMBL6279463 | 0.91 | CFTR (0.50) | CFTRKDM4EMEN1KMT2ANPSR1 | |
| SCHEMBL6504965 | 0.91 | CFTR (0.53) | CFTRKDM4EMEN1KMT2ANPSR1 | |
| SCHEMBL6274875 | 0.91 | CFTR (0.48) | CFTRKDM4EMEN1KMT2ANPSR1 | |
| SCHEMBL6277839 | 0.90 | CFTR (0.47) | CFTRKDM4EMEN1KMT2ANPSR1 | |
| SCHEMBL6277810 | 0.90 | CFTR (0.46) | CFTRKDM4EMEN1KMT2ANPSR1 | |
| SCHEMBL6278819 | 0.90 | CFTR (0.46) | CFTRKDM4EMEN1KMT2ANPSR1 | |
| SCHEMBL6280737 | 0.89 | CFTR (0.47) | CFTRKDM4EMEN1KMT2ANPSR1 | |
| SCHEMBL6504186 | 0.89 | CFTR (0.47) | CFTRKDM4EMEN1KMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288316-A1 | Beta-carbolines as growth hormone secretagogue receptor (GHSR) antagonists | BIOVITRUM AB (SE) | 2005-12-29 | — | — | US | claimed |
| US-20050288316-A1 | Beta-carbolines as growth hormone secretagogue receptor (GHSR) antagonists | BIOVITRUM AB (SE) | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288316-A1 | Beta-carbolines as growth hormone secretagogue receptor (GHSR) antagonists | GHSR, GHRHR, PRLHR | CFTR 589/4885KDM4E 4489/4885MEN1 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.